Sandoz ‘Surfs The Biosimilars Wave’ Despite US Natalizumab Delay
Although Small-Molecule Sales Are Flat In Q1 Overall, As North American Generics Decline
With Sandoz delivering first-quarter growth thanks to its booming biosimilars business – and despite flat sales of small-molecule generics that suffered from a downturn in North America – the company is “well on track to surf the biosimilars wave,” according to one analyst. However, Sandoz did report a delay to progress with its natalizumab biosimilar in the US that will push back launch.
